Antares Pharma, Inc. (ATRS)

[jab91252]

Also:

Pfizer Inc. (PFE)’s experimental pill for rheumatoid arthritis was as effective as Humira from Abbott Laboratories (ABT) and showed no new side effects in study results the company plans to submit for U.S. approval this year.

Nine study summaries were released today and will be presented at the American College of Rheumatology conference in Chicago in November. In one trial, both doses of Pfizer’s drug, called tofacitinib, were slightly more effective than Humira across six categories of improvement in symptoms and patient mobility, though the study wasn’t big enough to establish the pill’s superiority.

Pfizer, the world’s biggest drugmaker, designed tofacitinib to compete with injectable drugs that dominate the market, led by Humira from Abbott Park, Illinois-based Abbott, Johnson & Johnson (JNJ)’s Remicade and Amgen Inc. (AMGN)’s Enbrel, which New York-based Pfizer shares. The new drug may bring in more than $2.6 billion a year, said Catherine Arnold, an analyst at Credit Suisse Group AG in New York.

“This is a game-changing drug,” Arnold said. “Our peak sales of $2.6 billion are likely conservative.”


Repeating: "Pfizer, the world’s biggest drugmaker, designed tofacitinib to compete with injectable drugs that dominate the market."


We both know about Antares venture into the RA arena with VIBEX MTX - could this be a PFE transition to an injectable form of their drug, Tofacitinib, to further compete with Abbott, JNJ and AMGN??
jb